UMass Medical School’s MassBiologics has received an orphan drug designation from the U.S. Food and Drug Administration for MBL-HCV1, a monoclonal antibody developed to prevent the recurrence of hepatitis C virus in patients receiving a liver transplant.
“Anti-gal” technology developed at UMMS has been licensed to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers.
Job Dekker, PhD, and Noam Kaplan, PhD, have developed a new method for piecing together the short DNA reads produced by next-generation sequencing technologies that are the basis for building complete genome sequences.
Scientists at the UMMS and the Wellcome Trust Sanger Institute have discovered evidence that a widely used antifungal medicine increases susceptibility to flu infection in mice and cell cultures.
Neuroscientist Andrew Tapper and colleagues have identified the brain region in which nicotine withdrawal symptoms originate, revealing a potential target for smoking cessation therapies.
UMMS Professor Job Dekker, PhD, and colleagues show new evidence for a general principle of condensed, mitotic chromosome organization and structure that is highly adaptable and common to all cells. This computer simulation video shows the two-step process for a condensing chromosome, which happens as the cell moves from interphase to metaphase.
Using next generation sequencing and population genetic modeling, scientists at UMass Medical School and the Ecole Polytechnique Fédérale de Lausanne have found that cytomegalovirus evolves rapidly and dramatically in humans. These findings, published in PLoS Genetics, provide new genetic targets that could impede the evolution of CMV and prevent its spread.
Mitchell H. Sokoloff, MD, a urologic oncologist internationally known for his contributions to the surgical treatment of prostate, kidney and testis cancers, has been named chair of the newly established Department of Urology.